
The small SynuClean-D molecule interrupts the formation of the alpha-synuclein amyloid fibres responsible for the onset of Parkinson’s disease, and reverts the neurodegeneration caused by the disease. The study headed by UAB researchers was published in PNAS.
Parkinson’s disease is the second most common incurable neurodegenerative disorder after Alzheimer’s disease.
It is characterised by the accumulation of protein deposits in dopaminergic neurons (in charge of producing dopamine) in the form of amyloid fibres. These aggregates are formed mainly by the alpha-synuclein protein and in a very complex manner, which makes it complicated to identify molecules which could prevent or revert the process and the neurodegeneration associated with it.
A scientific collaboration led by researchers at the Institute of Biotechnology and Biomedicine (IBB) of the Universitat Autònoma de Barcelona has identified a molecule which halts and reverts this neurodegeneration. After analysing over 14,000 molecules, they found the SynuClean-D molecule, which inhibits the aggregation of the alpha-synuclein protein and breaks the already formed amyloid fibres, thus preventing the initiation of the process causing the onset of the neurodegenerative Parkinson’s disease.
Through experiments conducted with the small Caenorhabditis elegans worm, one of the most commonly used animal models in neurodegenerative diseases, researchers were able to verify that by administering it through food, the molecule was capable of notably reducing alpha-synuclein aggregations, preventing the spread of toxic aggregates and therefore avoiding the degeneration of dopaminergic neurons.
“Everything seems to indicate that the molecule we identified, the SynuClean-D, may provide therapeutic applications for the treatment of neurodegenerative disases such as Parkinson’s in the future”, UAB researcher and coordinator of the study Salvador Ventura points out.
To identify SynuClean-D researchers developed a methodology capable of indentifying the alpha-synuclein aggregation inhibitors among thousands of molecules. Once identified, an in vitro biophysical characterisation was conducted of their inhibiting activity and tests were run to discover their behaviour with human neural cell cultures, before testing it in animal models of the disease (the Caenorhabditis elegans worm). These animals express the alpha-synuclein in the muscle or in dopaminergic neurons. The experiments demonstrated that the administration of the identified inhibitor reduced protein aggregation, improving the mobility of the animal and protecting it from neural degeneration.
Learn more:Â Molecule capable of halting and reverting neurodegeneration caused by Parkinson’s disease identified
The Latest on: Parkinson’s
[google_news title=”” keyword=”Parkinson’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Parkinson’s
- Phil Parkinson on the Welcome to Wrexham cameras and beating Mourinhoon January 26, 2023 at 9:13 pm
Phil Parkinson's football journey has been varied, from players not getting paid for months at Bolton to now being a star on Disney Plus ...
- Movement disorder neurologist breaks down Parkinson’son January 26, 2023 at 7:10 am
Hear from UT Medical Movement Disorder Neurologist, Dr. Luis Zayas on how is research and practice is advancing the management of Parkinson’s. This event is put on by PJ Parkinson’s, an East Tennessee ...
- Inhibikase stock rises ~10% as FDA lifts clinical hold on Parkinson's studyon January 25, 2023 at 6:41 am
Inhibikase Therapeutics (NASDAQ:IKT) stock rose ~12% on Wednesday after the company said that the U.S. Food and Drug Administration (FDA) lifted a clinical hold on IkT-148009 in Parkinson's disease ...
- Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Diseaseon January 25, 2023 at 5:05 am
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's ...
- Using AI analysis of voice data to detect Parkinson's disease earlieron January 24, 2023 at 10:59 am
More than 10 million people worldwide are living with Parkinson's disease. There is no cure, but if symptoms are noticed early, the disease can be controlled. As Parkinson's disease progresses, along ...
- Altered speech may be the first sign of Parkinson's diseaseon January 24, 2023 at 8:50 am
Researchers attempted to identify early symptoms of Parkinson's disease using voice data. In their study, the researchers used artificial intelligence (AI) to analyze and assess speech signals, where ...
- Michael J. Fox says he became an alcoholic, hid Parkinson's diagnosis: 'There's no way out'on January 24, 2023 at 8:24 am
Michael J. Fox speaks about the "intense pain" of Parkinson's disease and how he used to cope in new documentary "Still," which premiered at Sundance.
- GRBJ—VAI partners with Cure Parkinson’s in clinical drug trialon January 24, 2023 at 2:30 am
The institute will contribute $1.3 million to test the effectiveness of the drug ambroxol. GRAND RAPIDS, Mich. — GRBJ— Van Andel Institute is contributing $1.3 million to a $6.6 million U.K. trial to ...
- Can You Test Yourself for Parkinson’s?on January 23, 2023 at 4:01 pm
For now, there is no reliable self-test you can use to diagnose Parkinson’s disease. If you notice early symptoms like tremors, stiffness, weakness, or others, see a healthcare professional for a full ...
via Bing News